WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205986
Description: Peretinoin, also known as NIK-333 , orally available, acyclic retinoid with potential antineoplastic and chemopreventive activities. Peretinoin binds to and activates nuclear retinoic acid receptors (RAR), which in turn recruit coactivator proteins and promote, with other transcriptional complexes, the transcription of target genes. As a result, this agent may modulate the expression of genes involved in the regulation of cell proliferation, cell differentiation, and apoptosis of both normal and tumor cells.
MedKoo Cat#: 205986
Chemical Formula: C20H30O2
Exact Mass: 302.22458
Molecular Weight: 302.451
Elemental Analysis: C, 79.42; H, 10.00; O, 10.58
Peretinoin, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: Peretinoin; NIK333
IUPAC/Chemical Name: (2E,4E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid
InChi Key: UUBHZHZSIKRVIV-KCXSXWJSSA-N
InChi Code: InChI=1S/C20H30O2/c1-16(2)9-6-10-17(3)11-7-12-18(4)13-8-14-19(5)15-20(21)22/h8-9,11,13-15H,6-7,10,12H2,1-5H3,(H,21,22)/b14-8+,17-11+,18-13+,19-15+
SMILES Code: C/C(C)=C/CC/C(C)=C/CC/C(C)=C/C=C/C(C)=C/C(O)=O
The following data is based on the product molecular weight 302.451 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Okusaka T, Ueno H, Ikeda M, Morizane C. Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res. 2011 Jun;41(6):542-52. doi: 10.1111/j.1872-034X.2011.00800.x. Epub 2011 Apr 19. PubMed PMID: 21501352.
2: Kimura M, Watanabe M, Ishibashi N, Yanagida S, Ogihara M. Acyclic retinoid NIK-333 accelerates liver regeneration and lowers serum transaminase activities in 70% partially hepatectomized rats, in vivo. Eur J Pharmacol. 2010 Sep 25;643(2-3):267-73. doi: 10.1016/j.ejphar.2010.06.037. Epub 2010 Jul 7. PubMed PMID: 20619257.
3: Tsujino T, Nagata T, Katoh F, Yamasaki H. Inhibition of Balb/c 3T3 cell transformation by synthetic acyclic retinoid NIK-333; possible involvement of enhanced gap junctional intercellular communication. Cancer Detect Prev. 2007;31(4):332-8. PubMed PMID: 17935907.
4: Okudaira T, Tomita M, Uchihara JN, Matsuda T, Ishikawa C, Kawakami H, Masuda M, Tanaka Y, Ohshiro K, Takasu N, Mori N. NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-kappaB signal pathway. Mol Cancer Ther. 2006 Mar;5(3):704-12. PubMed PMID: 16546985.
5: Kagawa M, Sano T, Ishibashi N, Hashimoto M, Okuno M, Moriwaki H, Suzuki R, Kohno H, Tanaka T. An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. Carcinogenesis. 2004 Jun;25(6):979-85. Epub 2004 Jan 23. PubMed PMID: 14742314.